

Name	Mr.NANDA KUMAR R	ID	MED110999644
Age & Gender	56/MALE	Visit Date	12/11/2022
Ref Doctor Name	MediWheel		

### ABDOMINO-PELVIC ULTRASONOGRAPHY

**LIVER** is normal in shape, size and has uniform echopattern. No evidence of focal lesion or intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

**GALL BLADDER** shows normal shape and has clear contents. Gall bladder wall is of normal thickness. CBD is of normal calibre.

**PANCREAS** has normal shape, size and uniform echopattern. No evidence of ductal dilatation or calcification.

**SPLEEN** shows normal shape, size and echopattern. Spleen measures 8.0cms in long axis. No demonstrable Para -aortic lymphadenopathy.

**KIDNEYS** move well with respiration and have normal shape, size and echopattern. Cortico- medullary differentiations are well madeout. No evidence of calculus or hydronephrosis.

**The kidney measures as follows:**

	<b>Bipolar length (cms)</b>	<b>Parenchymal thickness (cms)</b>
<b>Right Kidney</b>	<b>10.2</b>	<b>2.1</b>
<b>Left Kidney</b>	<b>10.0</b>	<b>1.1</b>

**URINARY BLADDER** shows normal shape and wall thickness. It has clear contents. No evidence of diverticula.

**PROSTATE** shows normal shape, size and echopattern. It measures 2.9 x 3.6 x 2.7cms (Vol:15cc).

No evidence of ascites / pleural effusion.

**IMPRESSION:**

➤ **NO SIGNIFICANT ABNORMALITY DETECTED.**

**DR. MANIMALA RUPA**

**REPORT DISCLAIMER**

1.This is only a radiological impression.Like other investigations, radiological investigation also have limitation. Therefore radiological reports should be interpreted in correlation with clinical and pathological findings.  
2.The results reported here in are subject to interpretation by qualified medical professionals only.  
3.Customer identities are accepted provided by the customer or their representative.  
4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.  
5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.  
6.Test results should be interpreted in context of clinical and other findings if any.In case of any clarification /doubt , the referring doctor/patient can contact the respective section head of the laboratory.

7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,  
8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.  
9.Liability is limited to the extend of amount billed.  
10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.  
11.Disputes,if any , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.

Name	Mr.NANDA KUMAR R	ID	MED110999644
Age & Gender	56/MALE	Visit Date	12/11/2022
Ref Doctor Name	MediWheel		

**CONSULTANT RADIOLOGIST**

MR/vp

**REPORT DISCLAIMER**

- 1.This is only a radiological impression.Like other investigations, radiological investigation also have limitation. Therefore radiological reports should be interpreted in correlation with clinical and pathological findings.
- 2.The results reported here in are subject to interpretation by qualified medical professionals only.
- 3.Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any.In case of any clarification /doubt , the referring doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- 11.Disputes,if any , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.



Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
Monocytes (EDTA Blood)	9.3	%	01 - 10
Basophils (Blood)	0.4	%	00 - 02
<b>INTERPRETATION:</b> Tests done on Automated Five Part cell counter. All abnormal results are reviewed and confirmed microscopically.			
Absolute Neutrophil count (EDTA Blood)	4.88	10 <sup>3</sup> / $\mu$ l	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood)	1.82	10 <sup>3</sup> / $\mu$ l	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood)	0.17	10 <sup>3</sup> / $\mu$ l	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood)	0.71	10 <sup>3</sup> / $\mu$ l	< 1.0
Absolute Basophil count (EDTA Blood)	0.03	10 <sup>3</sup> / $\mu$ l	< 0.2
Platelet Count (EDTA Blood)	231	10 <sup>3</sup> / $\mu$ l	150 - 450
MPV (EDTA Blood)	9.6	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.22	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Citratd Blood)	3	mm/hr	< 20

  
DR SHAMIM JAVED  
MD PATHOLOGY  
KMC 88902  
APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
<b><u>BIOCHEMISTRY</u></b>			
<b><u>Liver Function Test</u></b>			
Bilirubin(Total) (Serum/DCA with ATCS)	0.42	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.15	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.27	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/Modified IFCC)	12.38	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/Modified IFCC)	18.53	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	34.84	U/L	< 55
Alkaline Phosphatase (SAP) (Serum/Modified IFCC)	76.9	U/L	56 - 119
Total Protein (Serum/Biuret)	6.84	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.64	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.20	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	2.11		1.1 - 2.2

Anusha  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674

APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



---

<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
----------------------	-----------------------	-------------	--------------------------------------

**Lipid Profile**

Cholesterol Total (Serum/CHOD-PAP with ATCS)	230.84	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
---	--------	-------	--

Triglycerides (Serum/GPO-PAP with ATCS)	148.45	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500
--	--------	-------	---

**INTERPRETATION:** The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the 'usual\_ circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	38.30	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
---	-------	-------	--

LDL Cholesterol (Serum/Calculated)	162.8	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
---------------------------------------	-------	-------	---

VLDL Cholesterol (Serum/Calculated)	29.7	mg/dL	< 30
--	------	-------	------

Non HDL Cholesterol (Serum/Calculated)	192.5	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220
---	-------	-------	--

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
----------------------	-----------------------	-------------	--------------------------------------

**INTERPRETATION:** 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol.  
2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio (Serum/Calculated)	6		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
---	---	--	--

Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	3.9		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
--	-----	--	--

LDL/HDL Cholesterol Ratio (Serum/Calculated)	4.3		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
---	-----	--	---

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
<b><u>Glycosylated Haemoglobin (HbA1c)</u></b>			
HbA1C (Whole Blood/HPLC)	8.5	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: $\geq$ 6.5

**INTERPRETATION:** If Diabetes - Good control : 6.1 - 7.0 % , Fair control : 7.1 - 8.0 % , Poor control  $\geq$  8.1 %

Estimated Average Glucose 197.25 mg/dL  
(Whole Blood)

**INTERPRETATION: Comments**

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycaemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency, hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY



Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
----------------------	-----------------------	-------------	--------------------------------------

## IMMUNOASSAY

### THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total (Serum/ECLIA)	1.47	ng/mL	0.4 - 1.81
--	------	-------	------------

#### **INTERPRETATION:**

##### **Comment :**

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

T4 (Tyroxine) - Total (Serum/ECLIA)	10.07	µg/dL	4.2 - 12.0
--	-------	-------	------------

#### **INTERPRETATION:**

##### **Comment :**

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) (Serum/ECLIA)	3.25	µIU/mL	0.35 - 5.50
--	------	--------	-------------

#### **INTERPRETATION:**

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5

2 nd trimester 0.2-3.0

3 rd trimester : 0.3-3.0


(Indian Thyroid Society Guidelines)

##### **Comment :**

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.

2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM.The variation can be of the order of 50%,hence time of the day has influence on the measured serum TSH concentrations.

3.Values&amplt;0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.



APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



---

<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
----------------------	-----------------------	-------------	--------------------------------------

**CLINICAL PATHOLOGY**

**PHYSICAL EXAMINATION (URINE COMPLETE)**

Colour (Urine)	Yellow		Yellow to Amber
Appearance (Urine)	Clear		Clear
Volume(CLU) (Urine)	20		

**CHEMICAL EXAMINATION (URINE COMPLETE)**

pH (Urine)	5.0		4.5 - 8.0
Specific Gravity (Urine)	1.034		1.002 - 1.035
Ketone (Urine)	Negative		Negative
Urobilinogen (Urine)	Normal		Normal
Blood (Urine)	Negative		Negative
Nitrite (Urine)	Negative		Negative
Bilirubin (Urine)	Negative		Negative
Protein (Urine)	Negative		Negative

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674

APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
Glucose (Urine/GOD - POD)	Positive(+++)		Negative
Leukocytes(CP) (Urine)	Negative		Negative

**MICROSCOPIC EXAMINATION**  
**(URINE COMPLETE)**

Pus Cells (Urine)	0-1	/hpf	NIL
Epithelial Cells (Urine)	0-1	/hpf	NIL
RBCs (Urine)	NIL	/hpf	NIL
Others (Urine)	NIL		

**INTERPRETATION:**Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.

Casts (Urine)	NIL	/hpf	NIL
Crystals (Urine)	NIL	/hpf	NIL

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY

Name : Mr. NANDA KUMAR R

PID No. : MED110999644

SID No. : 422076936

Age / Sex : 56 Year(s) / Male

Type : OP

Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM

Collection On : 12/11/2022 9:25 AM

Report On : 12/11/2022 5:03 PM

Printed On : 08/12/2022 4:57 PM



Investigation

Observed  
Value

Unit

Biological  
Reference Interval

**IMMUNOHAEMATOLOGY**

BLOOD GROUPING AND Rh TYPING  
(EDTA Blood/Agglutination)

'O' Positive'

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
<b><u>BIOCHEMISTRY</u></b>			
BUN / Creatinine Ratio	11.5		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	<b>172.99</b>	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

**INTERPRETATION:** Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine) (Urine - F/GOD - POD)	+++		Negative
Glucose Postprandial (PPBS) (Plasma - PP/GOD-PAP)	<b>342.38</b>	mg/dL	70 - 140

**INTERPRETATION:**

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti-diabetic medication during treatment for Diabetes.

Urine Glucose(PP-2 hours) (Urine - PP)	+++		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV / derived)	12.6	mg/dL	7.0 - 21
Creatinine (Serum/Modified Jaffe)	1.09	mg/dL	0.9 - 1.3

**INTERPRETATION:** Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin ,cefazolin, ACE inhibitors ,angiotensin II receptor antagonists,N-acetylcyteine , chemotherapeutic agent such as flucytosine etc.

Uric Acid (Serum/Enzymatic)	5.48	mg/dL	3.5 - 7.2
--------------------------------	------	-------	-----------

  
Dr Anusha.K.S  
Sr.Consultant Pathologist  
Reg No : 100674  
APPROVED BY

Name : Mr. NANDA KUMAR R  
PID No. : MED110999644  
SID No. : 422076936  
Age / Sex : 56 Year(s) / Male  
Type : OP  
Ref. Dr : MediWheel

Register On : 12/11/2022 8:38 AM  
Collection On : 12/11/2022 9:25 AM  
Report On : 12/11/2022 5:03 PM  
Printed On : 08/12/2022 4:57 PM



<u>Investigation</u>	<u>Observed Value</u>	<u>Unit</u>	<u>Biological Reference Interval</u>
<b><u>IMMUNOASSAY</u></b>			
Prostate specific antigen - Total(PSA) (Serum/ <i>Manometric method</i> )	0.362	ng/mL	Normal: 0.0 - 4.0 Inflammatory & Non Malignant conditions of Prostate & genitourinary system: 4.01 - 10.0 Suspicious of Malignant disease of Prostate: > 10.0

**INTERPRETATION:** Analytical sensitivity: 0.008 - 100 ng/mL

PSA is a tumor marker for screening of prostate cancer. Increased levels of PSA are associated with prostate cancer and benign conditions like bacterial infection, inflammation of prostate gland and benign hypertrophy of prostate/ benign prostatic hyperplasia (BPH).

Transient elevation of PSA levels are seen following digital rectal examination, rigorous physical activity like bicycle riding, ejaculation within 24 hours.


PSA levels tend to increase in all men as they age.

Clinical Utility of PSA:

• In the early detection of Prostate cancer.

• As an aid in discriminating between Prostate cancer and Benign Prostatic disease.

• To detect cancer recurrence or disease progression.



APPROVED BY

-- End of Report --